Three scalp cooling abstracts to be presented at ESMO 2019

131

Pioneering scalp cooling research from India, Ireland and Italy will be presented at this year’s ESMO Congress 2019 (European Society for Medical Oncology) taking place in Barcelona, Spain, from 27th September – 1st October.

Research teams from the three hospitals, who have all used British developed Paxman Scalp Cooling Systems, will present their personal findings at the international exhibition to help raise awareness of the treatment and its clinical efficacy

ESMO 2019 is a global stage for excellence in translational research, presentation of practice-changing data and multidisciplinary discussions. The exhibition attracts clinicians, researchers, patient advocates, and the pharmaceutical industry from all over the world keen to learn about the latest advances in oncology, translating science into better cancer patient care.

The abstract presentations include:

The uptake, patient satisfaction and efficacy of scalp cooling among patients receiving chemotherapy in an Irish oncology day ward. Speaker: William Maher (Cork, Ireland)

Scalp cooler is effective in reducing chemotherapy-induced alopecia among breast cancer patients: a single institution experience. Speaker: Emilia Gianotti (Carpi, Italy)

Randomised controlled trial of Scalp Cooling (SC) for the prevention of Chemotherapy Induced Alopecia (CIA). Speaker: Jyoti Bajpai (Mumbai, India)

Speaking about her research Dr Bajpai, Professor in Medical Oncology from Tata Memorial Hospital, Mumbai, India, said: “Hair loss is a well-known side effect of many chemotherapy regimens, with many of our patients reporting it to be the most traumatic aspect of their treatment. There are also culturally many misconceptions and stigma attached to hair loss, for example one woman patient from Uttar Pradesh was thrown out of her house by her husband and in-laws because of her baldness. Her teenaged daughters were also asked to leave with her. The family considered her disease and baldness to be an outcome of past sins. The fear of cancer becomes secondary and the fact that they will lose hair during treatment takes centre stage.”

The Paxman Scalp Cooling System is available at a large number of cancer centres in Europe, North- and South America, Asia and Australia. With close to 3,500 delivered systems to over 40 countries, Paxman has established itself as the leading player in its field. The award-winning technology is Shonin, Ninsho and FDA cleared and is proven to help cancer patients keep their hair during chemotherapy treatment.

CEO Richard Paxman added: “We are delighted that real-life data and research from around the globe will be presented at ESMO by a number of leading clinicians. There have been a number of significant steps recently that have helped bring scalp cooling to the forefront of people’s minds, and research presentations like these continue this education and awareness-building. It is an exciting time for scalp cooling, and we are delighted to be part of it.”

Scalp cooling provides the only real alternative to hair loss, resulting in a high level of retention or even complete hair preservation, improving patients’ self-confidence and creating positive attitudes towards treatment.

To find out more, visit the Paxman team at ESMO booth number 418.

About Paxman
The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. Paxman’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. To find out more visit: www.paxmanscalpcooling.com